Compare Ascendis Pharma A/S (ASND) vs BigBearai Holdings Inc (BBAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs BigBearai Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while BigBearai Holdings Inc trades at $3.25 (market cap $1.57B). The key difference: Ascendis Pharma A/S is far larger — about 11.3× BigBearai Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BBAI | |
|---|---|---|
Market Cap | $17.74B | $1.57B |
Sector | Health | Technology |
52-Week High | $277.18 | $8.91 |
52-Week Low | $163.32 | $3.05 |
Enterprise Value | $18.11B | $1.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BigBear.ai (BBAI) trades at $3.27, down 1.51% amid bearish technical signals. The company shows persistent losses with a -226.69% net income margin despite steady $127M revenue. Recent Dutch approval for airport security technology highlights growth potential, but high SG&A expenses and negative cash flow from operations remain concerns. Technical indicators show oversold conditions with RSI at 25.86, though moving averages signal continued bearish pressure.
BBAI faces significant execution risks with negative profitability metrics, though analyst consensus leans neutral with 75% hold ratings. The stock's outlook depends on converting AI contract wins into sustainable profitability, with current valuation appearing rich given ongoing losses. Near-term catalysts include Q2 2026 earnings and defense contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →
